These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 20683319

  • 1. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
    Delaugerre C, Charreau I, Braun J, Néré ML, de Castro N, Yeni P, Ghosn J, Aboulker JP, Molina JM, Simon F, ANRS 138 study group.
    AIDS; 2010 Sep 24; 24(15):2391-5. PubMed ID: 20683319
    [Abstract] [Full Text] [Related]

  • 2. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
    Reigadas S, Andréola ML, Wittkop L, Cosnefroy O, Anies G, Recordon-Pinson P, Thiébaut R, Masquelier B, Fleury H.
    J Antimicrob Chemother; 2010 Mar 24; 65(3):434-7. PubMed ID: 20051476
    [Abstract] [Full Text] [Related]

  • 3. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR.
    AIDS; 2012 Jan 14; 26(2):167-74. PubMed ID: 22089379
    [Abstract] [Full Text] [Related]

  • 4. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E, Tommasi C, Abbate I, Bonora S, Tempestilli M, Bellagamba R, Viscione M, Rozera G, Gallo AL, Ivanovic J, Amendola A, Pucillo L, Di Perri G, Capobianchi MR, Narciso P.
    Antivir Ther; 2011 Jan 14; 16(6):797-803. PubMed ID: 21900711
    [Abstract] [Full Text] [Related]

  • 5. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
    Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J.
    Nat Med; 2010 Apr 14; 16(4):460-5. PubMed ID: 20228817
    [Abstract] [Full Text] [Related]

  • 6. Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia.
    McDermott JL, Martini I, Ferrari D, Bertolotti F, Giacomazzi C, Murdaca G, Puppo F, Indiveri F, Varnier OE.
    J Clin Microbiol; 2005 Oct 14; 43(10):5272-4. PubMed ID: 16207994
    [Abstract] [Full Text] [Related]

  • 7. HIV-1 and HIV-2 produce different amounts of 2-long terminal repeat circular DNA in vitro.
    Gueudin M, Braun J, Plantier JC, Simon F.
    AIDS; 2008 Nov 30; 22(18):2543-5. PubMed ID: 19005280
    [Abstract] [Full Text] [Related]

  • 8. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.
    J Med Virol; 2004 Jul 30; 73(3):350-61. PubMed ID: 15170628
    [Abstract] [Full Text] [Related]

  • 9. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R, Jørgensen LB, Møller BK, Black FT, Kjems J, Obel N.
    J Clin Virol; 2005 Dec 30; 34(4):257-67. PubMed ID: 16286049
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
    Stephan C, Baldauf HM, Barry J, Giordano FA, Bartholomae CC, Haberl A, Bickel M, Schmidt M, Laufs S, Kaderali L, Keppler OT.
    J Antimicrob Chemother; 2014 Oct 30; 69(10):2809-18. PubMed ID: 24962031
    [Abstract] [Full Text] [Related]

  • 13. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
    Seclén E, Del Mar González M, De Mendoza C, Soriano V, Poveda E.
    J Antimicrob Chemother; 2010 Jul 30; 65(7):1493-6. PubMed ID: 20488982
    [Abstract] [Full Text] [Related]

  • 14. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
    Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ, AIDS Clinical Trials Group (ACTG) A5244 Team.
    J Acquir Immune Defic Syndr; 2012 Mar 01; 59(3):229-35. PubMed ID: 22083073
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
    Cardozo EF, Luo R, Piovoso MJ, Zurakowski R.
    J Theor Biol; 2014 Mar 21; 345():61-9. PubMed ID: 24378646
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
    Buzón MJ, Codoñer FM, Frost SD, Pou C, Puertas MC, Massanella M, Dalmau J, Llibre JM, Stevenson M, Blanco J, Clotet B, Paredes R, Martinez-Picado J.
    PLoS Pathog; 2011 Oct 21; 7(10):e1002314. PubMed ID: 22046128
    [Abstract] [Full Text] [Related]

  • 19. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
    Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG.
    J Infect Dis; 2013 Nov 01; 208(9):1436-42. PubMed ID: 23975885
    [Abstract] [Full Text] [Related]

  • 20. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
    Dornadula G, Nunnari G, Vanella M, Roman J, Babinchak T, DeSimone J, Stern J, Braffman M, Zhang H, Pomerantz RJ.
    J Infect Dis; 2001 Jun 01; 183(11):1682-7. PubMed ID: 11343220
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.